Wockhardt has signed an in-licensing agreement with LSI, a UK-based company specializing in dermatology, to market Vitix, a patented product for the treatment of vitiligo, a pigmentation disorder.

The company has planned to expand its portfolio in cardiology, diabetology & dermatology by introducing new proved products.

Vitix, a gel for topical application, will be manufactured by Wockhardt in India using the active pharmaceutical ingredients (API) imported from LSI.